1-8 of 8
Chris E. Lawrence
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Youn H Kim, MD, Richard T. Hoppe, MD, Alain H Rook, MD, Amit Maity, MD PhD, Larisa J Geskin, MD, David P Horowitz, MD, Genet Finnegan, MHS, PA-C, Michael Khodadoust, MD PhD, Wen-Kai Weng, MD PhD, Analuisa Lares, ANP, BSN, RN, Eric Ki Jun Hong, BS, Marie Buchanan, RN, Vernon Ma, BS, Hue Kha, BS, Chris E Lawrence, PhD, Vladimir Vainstein, MD, Lena A Basile, PhD JD
Journal: Blood
Blood (2016) 128 (22): 4165.
https://doi.org/10.1182/blood.V128.22.4165.4165
Published: 2016
Journal Articles

Recombinant Human IL-12 Exerts Differential Effects on Circulating CD56 bright and CD56 dim NK Cells in Healthy Human Subjects

Simmy Thomas, PhD, Chris E Lawrence, PhD, Vernon Mar, MS, Hue Kha, MS, Lena A Basile, PhD JD
Journal: Blood
Blood (2014) 124 (21): 756.
https://doi.org/10.1182/blood.V124.21.756.756
Published: 2014
Journal Articles

Recombinant Human IL-12 Promotes NK Cell Migration: Increased CXCL10, Co-Receptors IL-12Rβ2 and CXCR3, and Bright CD56 NK Cells In Healthy Human Subjects

Simmy Thomas, PhD, Chris E. Lawrence, PhD, Vernon Mar, MS, Hue Kha, MS, Vladimir Vainstein, MD, MS, Mamata Gokhale, PhD, Lena A. Basile, PhD, JD
Journal: Blood
Blood (2013) 122 (21): 3481.
https://doi.org/10.1182/blood.V122.21.3481.3481
Published: 2013
Journal Articles

The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates

Jonathan Zalevsky, Irene W. L. Leung, Sher Karki, Seung Y. Chu, Eugene A. Zhukovsky, John R. Desjarlais, David F. Carmichael, Chris E. Lawrence
Journal: Blood
Blood (2009) 113 (16): 3735–3743.
https://doi.org/10.1182/blood-2008-10-182048
Published: 2009
Journal Articles

Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Anas Younes, MD, Jonathan Zalevsky, PhD, Kristie A. Blum, MD, Mitchell R Smith, MD, PhD, Henry C. Fung, MD, David A Ramies, MD, Chris E Lawrence, PhD, Daniel Combs, BS, Jeffrey Bloss, MD
Journal: Blood
Blood (2008) 112 (11): 5012.
https://doi.org/10.1182/blood.V112.11.5012.5012
Published: 2008
Journal Articles

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Chris E Lawrence, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Irene Leung, PhD, Seung Chu, PhD, Sher Karki, PhD, Eugene Zhukovsky, PhD, John R Desjarlais, PhD, David F Carmichael, PhD
Journal: Blood
Blood (2008) 112 (11): 2621.
https://doi.org/10.1182/blood.V112.11.2621.2621
Published: 2008
Journal Articles

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Chris E. Lawrence, PhD, Phil W. Hammond, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Seung Chu, PhD, Sher Karki, PhD, John R. Desjarlais, PhD, David F. Carmichael, PhD
Journal: Blood
Blood (2007) 110 (11): 2340.
https://doi.org/10.1182/blood.V110.11.2340.2340
Published: 2007
Journal Articles

SNS-595, a Novel S-Phase Active Cytotoxic, Demonstrates Pharmacologic Properties Appropriate for the Treatment of Advanced Hematologic Malignancies.

Chris E. Lawrence, BS, PhD, Jen P. Arbitrario, BS, Jeff L. Kumer, BS, MS
Journal: Blood
Blood (2005) 106 (11): 4632.
https://doi.org/10.1182/blood.V106.11.4632.4632
Published: 2005